CTNS and breast carcinoma: Thus, the PROACT trial does not support the use of enalapril in this setting.PerspectivesCOMPETENCY IN MEDICAL KNOWLEDGE OR PATIENT CARE: The PROACT randomized controlled trial, which included 111 patients receiving ≥300 mg/m2 doxorubicin equivalent chemotherapy for breast cancer or NHL, demonstrated that enalapril, administered at a mean dose of 17.7 mg daily, did not protect against markers of cardiac injury such as cTns or cardiac dysfunction.